Esteve's E-58425 meets in Phase II pain trial

Esteve S.A. (Barcelona, Spain) said 100, 150 and 200 mg doses of E-58425 met the primary endpoint of improving summed pain intensity difference (SPID) scores at eight hours vs. both placebo (p<0.0002)...